Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.64 |
| ▸ | CA4 | P22748 | 4/20 | 0.47 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL3173468 | 1.00 | — | — | |
| Acetic Acid SCHEMBL8206910 | 1.00 | — | — | |
| Acetic Acid SCHEMBL27972026 | 0.97 | CA1 (0.60) | CA1CA4FAHD1CA2LMNA | |
| Acetic Acid SCHEMBL10534378 | 0.97 | CA1 (0.60) | CA1CA4FAHD1CA2LMNA | |
| Acetic Acid SCHEMBL28015778 | 0.94 | CA1 (0.56) | CA1CA4FAHD1CA2FFAR3 | |
| Acetic Acid SCHEMBL29046887 | 0.93 | CA1 (0.57) | CA1CA4LMNAFFAR3TDP1 | |
| Acetic Acid SCHEMBL28420347 | 0.93 | CA1 (0.57) | CA1CA4LMNAFFAR3TDP1 | |
| Acetic Acid SCHEMBL27897081 | 0.93 | CA1 (0.57) | CA1CA4LMNAFFAR3TDP1 | |
| Acetic Acid SCHEMBL17747086 | 0.93 | CA1 (0.57) | CA1CA4LMNAFFAR3TDP1 | |
| Acetic Acid SCHEMBL28318641 | 0.93 | CA1 (0.57) | CA1CA4LMNAFFAR3TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114081185-A | Gamma-aminobutyric acid detection method and composition for improving sleep and resisting anxiety | 程新 | 2022-02-25 | — | — | CN | disclosed |
| CN-110596293-B | High performance liquid detection method for homopiperazine | 山东威高药业股份有限公司 | 2021-07-20 | — | — | CN | disclosed |
| CN-110596293-A | High performance liquid detection method for homopiperazine | 山东威高药业股份有限公司 | 2019-12-20 | — | — | CN | disclosed |
| EP-1654283-B1 | IMPROVED METHOD OF PURIFYING TFPI AND TFPI ANALOGS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2011-07-13 | — | — | EP | disclosed |
| US-7851433-B2 | Method of purifying TFPI and TFPI analogs | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-20080281084-A1 | Formulation, Solubilization, Purification, and Refolding of Tissue Factor Pathway Inhibitor | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| EP-1589949-B1 | STABILIZED LYOPHILIZED COMPOSITIONS COMPRISING TISSUE FACTOR PATHWAY INHIBITOR OR TISSUE FACTOR PATHWAY INHIBITOR VARIANTS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1803445-A2 | Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-07-04 | — | — | EP | disclosed |
| US-7226757-B2 | Formulation, solubilization, purification, and refolding of tissue factor pathway inhibitor | G.D. SEARLE LLC (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1602667-B1 | Aqueous formulation comprising TFPI and solubilizing agents | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2007-04-04 | — | — | EP | disclosed |
| WO-2005019265-A1 | IMPROVED METHOD OF PURIFYING TFPI AND TFPI ANALOGS | CHIRON CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050037475-A1 | Method of purifying TFPI and TFPI analogs | CHIRON CORPORATION (US) | 2005-02-17 | — | — | US | disclosed |
| US-20040180827-A1 | Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants | CHIRON CORPORATION (US) | 2004-09-16 | — | — | US | disclosed |
| WO-2004062646-A1 | STABILIZED LYOPHILIZED COMPOSITIONS COMPRISING TISSUE FACTOR PATHWAY INHIBITOR OR TISSUE FACTOR PATHWAY INHIBITOR VARIANTS | CHIRON CORPORATION (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20020137884-A1 | Formulation, solubilization, purification, and refolding of tissue factor pathway inhibitor | CHIRON CORPORATION | 2002-09-26 | — | — | US | disclosed |
| US-6323326-B1 | MIXTURE OF TISSUE FACTOR PATHWAY IHIBITOR; FOR USE IN PREVENTION OF THROMBOSIS DURING VASCULAR SUSTEM SURGERY; FOR PREVENTION OF SEPSIS | CHIRON CORPORATION | 2001-11-27 | — | — | US | disclosed |
| US-6319896-B1 | ADDING AQUEOUS SOLUTION OF CHARGED POLYMER TO SOLUTION OF PURIFIED PROTEIN TO REDUCE INTERMOLECULAR OR INTRAMOLECULAR INTERACTIONS BETWEEN THE POSITIVELY AND NEGATIVELY CHARGED DOMAINS WHEREBY SOLUBILITY OF PROTEIN IS INCREASED | CHIRON CORPORATION | 2001-11-20 | — | — | US | disclosed |
| US-5888968-A | TFPI formulation | CHIRON CORPORATION (US) | 1999-03-30 | — | — | US | disclosed |
| EP-0837883-A2 | METHOD OF SOLUBILIZING, PURIFYING, AND REFOLDING PROTEIN | CHIRON CORPORATION (US) | 1998-04-29 | — | — | EP | disclosed |
| WO-1996040784-A2 | METHOD OF SOLUBILIZING, PURIFYING, AND REFOLDING PROTEIN | CHIRON CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |